Clinical research of traditional Chinese medicine injection combined with XELOX regimen in the treatment of 97 cases of colorectal cancer
|Beijing University of Traditional Chinese Medicine
|Traditional Chinese Medicine
|Kang’ai injection The listed again after evaluation colorectal cancer clinicalmonitoring
Objective:To evaluate the efficacy and safety of Kang’ai injection in treatment of colorectal cancer. This controlled study was to compared the clinical efficacy, side effect, clinical symptom and quality of life of XELOX regimen plus Kang’ai injection and XELOX regimen chemotherapy alone.Methods:A multicenter, randomized controlled trial was conducted.150patients with colorectal cancer into the group. Recycled97cases, the effective cases are95. Trial group(n=49)and control group(n=46). The patients in the trial group received Kang’ai injection combined XELOX regimen chemotherapy, the patients in the control group received chemotherapy alone. The regimen of chemotherapy used here was XELOX, which apply oxaliplatin130mg/m2(dl),Capecitabine1000mg/m2(dl-14),take3weeks as1cycle,administrated2cycles. To the treating group,in the same time of applying chemotherapy,60ml of Kang’ai injection was given intravenously by dissolving in250ml of glucose or normal saline injection per day for14successive days,21days for a course of treatment. The efficacy, adverse effects, clinical symptom, KPS and quality of life of the two groups were evaluated.Results:1.The pass rates of the experimental group and the control group were91.84%and89.13%, respectively(P>0.05).There was no statistically significant difference between the two groups.2.The rate of the adverse effects, the experimental group and the control group were23.61%and32.92%, respectively(p<0.05).There was statistically significant difference between the two groups.3.While the clinical symptom was significantly improved in the experimental group as compared with the control group, the rates of improvement were 83.67%and60.87%respectively(P<0.05).4.The KPS was no statistically difference between the two groups. The improvement rates of KPS were81.63%and71.74%respectively(P>0.05).5.The quality of life was significantly improved in the experimental group, mainly reflected in symptoms and emotion sub scales (P<0.05).6. Just1patient occur adverse reactions in treating group, but we can’t judge it’s relationship with Kang’ai injection clearly. Conclusion: XELOX regimen combined with Kang’ai injection can relieve adverse effects, amendment clinical symptom improve the quality of life, but cannot increase pass rate and improve KPS for colorectal cancer patients when compared with chemotherapy alone; for colorectal cancer patients, Kang’ai injection combined with chemotherapy in the treatment of advanced colorectal cancer have a certain clinical value.